文献速递炎症性肠病胃肠动力与功能性疾病

粪便微生物移植治疗溃疡性结肠炎有效供体的微生物决定因素

Microbial determinants of effective donors in faecal microbiota transplantation for UC.
PubMed 文献 · Gut · 2022-07-25

该研究比较了两名粪便微生物移植供体的肠道微生物组与代谢组,其中一名供体在溃疡性结肠炎患者中诱导缓解的疗效为100%,另一名为36%。有效供体的微生物组长期稳定性高、物种均匀度好,且物种均匀度与两项临床试验的疗效相关,并促进供体物种在患者体内定植。

要点

  • 有效供体肠道微生物组长期稳定性高度明显,物种均匀度是与疗效相关的稳健特征。
  • 供体微生物物种均匀度与两项粪便微生物移植治疗溃疡性结肠炎临床试验的临床疗效相关。
  • 两名供体间有90种细菌和1种古菌差异丰富,其中44种相对丰度>0.1%。

核心结论

  • 供体微生物组稳定性和物种均匀度被确定为与溃疡性结肠炎治疗疗效相关的新指标,超越单个微生物物种或代谢物。
  • 这些指标可能代表群落韧性,转化为宿主中更好的定植。

研究设计与样本

  • 收集两名供体的粪便样本,供体1历时44周,供体2历时70周。
  • 使用鸟枪法宏基因组学和非靶向代谢组学对微生物组和代谢组进行表征。

主要发现

  • 有效供体的肠道微生物组长期稳定性高度明显。
  • 供体微生物物种均匀度是与两项溃疡性结肠炎粪便微生物移植临床试验临床疗效相关的稳健特征,导致患者中供体物种定植增加。
  • 供体肠道微生物群的α多样性和β多样性显著不同。
  • 两名供体间有90种细菌和1种古菌差异丰富,其中44种相对丰度>0.1%。
  • 44种中有17种在有效供体中富集,其中11种(64.7%)组装成高质量基因组,在该供体中普遍存在(≥75%样本),6种显示在患者中定植的证据。

关键数值与推荐

  • 一名供体疗效为100%,另一名供体疗效为36%。
  • 44种差异丰富物种中,17种在有效供体中富集,11种(64.7%)组装成高质量基因组,在该供体中普遍存在(≥75%样本),6种显示在患者中定植的证据。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Faecal microbiota transplantation (FMT) has variable efficacy in treating UC. Recently, oral lyophilised FMT was found to induce remission in patients with UC, with one donor having 100% efficacy compared with a second donor (36% efficacy). We characterised differences in the gut microbiota of these two donors with the aim of improving FMT donor selection. DESIGN: Faecal samples from the two donors were collected over a period of 44 (donor 1) or 70 (donor 2) weeks. The microbiome and metabolome were profiled using shotgun metagenomics and untargeted metabolomics RESULTS: Gut microbiome long-term stability was highly evident in the effective donor. Donor microbiota species evenness was a robust feature associated with clinical efficacy across two clinical trials of FMT in UC, leading to increased donor species engraftment in patients. Alpha diversity and beta diversity of donor gut microbiotas significantly differed. 90 bacterial species and one archaeon were differentially abundant between donors, 44 of which were >0.1% in relative abundance. 17/44 species were enriched in the effective donor, 11 of which (64.7%) were assembled into high-quality genomes that were prevalent (≥75% samples) in that donor, and six showed evidence of engraftment in patients. Taxonomic differences between donors translated to substantial microbial functional differences that were validated using metabolomics. CONCLUSION: Donor microbiota stability and species evenness were identified as novel metrics that were associated with therapeutic efficacy in UC, beyond individual microbial species or metabolites. These metrics may represent community resilience that translates to better engraftment in the host. TRIAL REGISTRATION NUMBER: ACTRN12619000611123.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Haifer C, Luu LDW, Paramsothy S, et al. Microbial determinants of effective donors in faecal microbiota transplantation for UC. Gut. 2022. PMID: 35879048. doi:10.1136/gutjnl-2022-327742

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。